LKM724F • October 2021 • US$3,850
The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. Several targeted therapeutics leukemia indications, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. Their approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of Leukemias and related blood cancers. This report examines two dozen targeted therapeutics leukemia indications including therapeutic drugs targeting leukemias, and their mechanisms of action.
Target Oncology Therapeutics: Leukemias – What You Will Learn
• What is the market share of approved Leukemia therapeutics?
• What is the global supply picture for targeted therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic coverage across all oncology indications? What are the product opportunities?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive picture for the Leukemia market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation Leukemia therapeutics?
Summary of Contents
Targeted Oncology Therapeutics
The Recombinant Drug Ecosystem
mAbs and Targeted Oncology Therapeutics
Tyrosine Kinase Inhibitors
Biological Drug Activity by Region
Oncology mAbs – Competitive Considerations
Historical Growth of Biologicals
Supply Chain Factors
Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Approved Biological Drugs for Leukemias
Monoclonal Antibodies Indicated for Leukemias
The Addressable Market
Drugs in Development – The Clinical Trial Picture
FDA-Approved Targeted Oncology Therapeutics for Leukemia